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ABSTRACT 
 
Histone H3 lysine 9 dimethylation (H3K9me2) is mainly regulated by the histone 
lysine methyltransferase G9a and is associated with the repression of transcription. 
However, both the role of G9a and the significance of H3K9me2 in hepatocellular 
carcinoma (HCC) cells remain unclear. In this study, we conducted loss-of-function 
assay of G9a using short-hairpin RNA and pharmacological interference. Knockdown 
of G9a reduced H3K9me2 levels and impaired both HCC cell growth and sphere 
formation. However, transforming growth factor β1-induced epithelial mesenchymal 
transition (EMT) was not suppressed by G9a knockdown. Combined analyses of 
chromatin immunoprecipitation followed by sequencing and RNA-sequencing led to 
successful identification of 96 candidate epigenetic targets of G9a. Pharmacological 
inhibition of G9a by BIX-01294 resulted in both cell growth inhibition and induction 
of apoptosis in HCC cells. Intraperitoneal administration of BIX-01294 suppressed 
the growth of xenograft tumors generated by implantation of HCC cells in non-obese 
diabetic/severe combined immunodeficient mice. Immunohistochemical analyses 
revealed high levels of G9a and H3K9me2 in 36 (66.7%) and 35 (64.8%) primary HCC 
tissues, respectively. G9a expression levels were significantly positively correlated 
with H3K9me2 levels in tumor tissues. In contrast, in non-tumor tissues, G9a and 
H3K9me2 were only observed in biliary epithelial cells and periportal hepatocytes. 
In conclusion, G9a inhibition impairs anchorage-dependent and -independent cell 
growth, but not EMT in HCC cells. Our data indicate that pharmacological interference 
of G9a might be a novel epigenetic approach for the treatment of HCC. 
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(NOD/SCID), RNA-sequencing (RNA-seq), transforming growth factor β1 (TGF-β1). 
                                         
4 
INTRODUCTION 
 
Epigenetics is defined as a mechanism that regulates gene expression without 
changes in the underlying DNA sequence [1]. Epigenetic regulation of chromatin 
structure is achieved through various approaches, including histone modifications, DNA 
methylation, small and non-coding RNAs, and chromatin remodeling [2]. Among these 
epigenetic changes, Methylation of histone H3 at lysine 4 (H3K4) and histone H3 at 
lysine 36 (H3K36) is associated with transcriptional activation, while methylation of 
histone H3 at lysine 9 (H3K9) and histone H3 at lysine 27 (H3K27) is involved in 
transcriptional repression [3]. Histone lysine methyltransferases (HKMTs) typically 
contain a SET domain and can transfer methyl groups to specific histone tail lysine 
residues [4]. SUV39H1, ESET, G9a and GLP function as H3K9-specific HKMTs and 
the methylation of H3K9 has been shown to play an important role in both gene 
repression and heterochromatin formation [5]. G9a is also a member of the SUV39H 
group and is responsible for H3K9 mono- and dimethylation (H3K9me2) [6].  
Aberrant epigenetic modifications are frequently observed in a wide range of cancers 
and are considered to play a central role in carcinogenesis and cancer progression [7]. 
G9a overexpression has been reported in various types of cancers, including HCC [8, 9]. 
High levels of G9a expression are also considered to be associated with poor prognosis 
in some cancers [10]. Bai et al. recently reported that G9a overexpression serves as a 
predictor of unfavorable survival rates after liver resection in patients with HCC [11]. 
Although these findings indicate that G9a is a potential therapeutic target for HCC, the 
role of G9a and biological function of H3K9me2 in HCC remains to be elucidated. 
In the present study, we performed loss-of-function analyses of G9a using 
lentivirus-mediated knockdown of G9a in culture. Candidate targets of G9a were 
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investigated by chromatin immunoprecipitation followed by sequencing (ChIP-seq) and 
RNA-sequencing (RNA-seq). In addition, pharmacological disruption of G9a was 
conducted in culture as well as in vivo xenograft models. Finally, G9a expression levels 
and H3K9me2 levels in primary HCC surgical samples were determined by 
immunohistochemical analyses. 
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RESULTS 
 
Basal expression of G9a and H3K9me2 level 
We first examined the basal expression of G9a and H3K9me2 levels in a number of 
different HCC cell lines, namely Huh1, Huh7, PLC/PRF/5, and Huh6 cells (Figure 1). 
Immunocytochemical analyses demonstrated that G9a was highly expressed in the 
nuclei of almost all HCC cells. Similar to G9a expression, high H3K9me2 levels were 
also found in the nuclei of HCC cells. These results suggest that G9a and H3K9me2 
levels are closely associated in HCC cells. 
 
Loss-of-function analyses of G9a in HCC cells 
To investigate the role of G9a in HCC cells, we first conducted G9a knockdown 
experiments in vitro. We achieved the stable knockdown of G9a in Huh1 and Huh7 cells 
using lentivirus-mediated shRNA directed against G9a by enhanced green fluorescent 
protein (EGFP)-positive cell sorting. A lentiviral vector expressing the shRNA targeted 
against luciferase (Luc) was used as a control. Two different shRNAs (sh-G9a-1 and 
sh-G9a-2) were able to suppress G9a protein expression as well as reduce H3K9me2 
levels (Figures 2A). Although both shRNAs interfered with cell growth and sphere 
formation, sh-G9a-2 showed a more pronounced inhibitory effect than sh-G9a-1 
(Figures 2B-2D). We then performed xenograft transplantation of sh-G9a-2-expressing 
Huh1 and Huh7 cells using NOD/SCID mice (Supplementary Figure S1). 
G9a-knockdown HCC cell-derived tumors showed delayed onset and slower tumor 
growth compared with sh-Luc-expressing control cell-derived tumors. Altogether, these 
results indicate that G9a expression and H3K9me2 levels closely affect the cell growth 
and tumorigenicity of HCC cells. 
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Role of G9a in epithelial mesenchymal transition of HCC cells 
It has been reported that G9a plays an important role in epithelial mesenchymal 
transition (EMT) in several cancers such as breast cancer and head and neck squamous 
cell carcinoma [12, 13]. Interaction between G9a and EMT-related transcription factor 
SNAIL contributes to E-cadherin repression in human breast cancer cells. 
Co-immunoprecipitation (co-IP) of endogenous SNAIL and G9a in Huh7 and 293T 
cells confirmed a physical interaction occurring between G9a and SNAIL (Figure 3A). 
Therefore, we examined the effect of G9a depletion upon transforming growth factor β1 
(TGF-β1)-induced EMT in Huh7 and PLC/PRF/5 cells. Epithelial phenotype of these 
HCC cells showed no remarkable changes after G9a knockdown (Figure 3B and 
Supplementary Figures 2A and 2B). TGF-β1 treatment successfully changed the 
epithelial cobblestone morphology to a spindle-like fibroblastic morphology (Figure 3B 
and Supplementary Figure 2A). However, G9a knockdown failed to block 
TGF-β1-induced EMT in both HCC cells (Figure 3C and Supplementary Figure 2C). 
Immunocytochemical analyses showed that TGF-β1 treatment reduced expression of 
E-cadherin in both control and G9a knockdown cells (Figure 3C and Supplementary 
Figure 2B). Concordant with these findings, TGF-β1 treatment of control or G9a 
knockdown cells resulted in identical degrees of up-regulation of SNAIL as well as 
mesenchymal markers, including N-cadherin, Fibronectin1, and Vimentin (Figure 3D 
and Supplementary Figure 2D). In addition, wound healing assay showed no remarkable 
differences in cellular migration between control and G9a knockdown Huh7 cells 
(Supplementary Figure 3).  
Given that miR-200 inhibits TGF-β1-induced E-cadherin downregulation [14], we 
examined miR-200 role in G9a knockdown HCC cells. miR200a and 200b expression 
levels showed no significant changes after G9a knockdown (Supplementary Figure 4A). 
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Furthermore, miR200a overexpression inhibited TGF-β1-induced E-cadherin repression 
in G9a knockdown cells and in control cells. (Supplementary Figure 4B and 4C). 
Collectively, these results imply that G9a minimally affects TGF-β1-induced EMT in 
HCC cells and that other regulatory mechanisms that involve miR200 might be more 
important in EMT induction. 
 
Exploration of candidate target for G9a 
To evaluate the epigenetic changes in G9a knockdown, we performed ChIP-seq of 
H3K9me2 in control and G9a knockdown Huh7 cells. ChIP-seq profiling successfully 
demonstrated that G9a knockdown resulted in a marked decrease in H3K9me2 levels in 
the promoters of coding genes (2.0 kb ± TSS) (Figure 4A). The number of genes with 
reduced H3K9me2 levels (<0.5-fold expression) in G9a knockdown cells compared 
with those in control cells, was 4,358. 
We next performed RNA-seq for assessing changes in gene expression after G9a 
knockdown. RNA-seq profiling identified 371 upregulated (>2-fold expression) and 141 
downregulated (<0.5-fold expression) genes. Combined examination of RNA-seq 
profiling and ChIP-seq data led to successful identification of 96 candidate targets for 
G9a whose expression was de-repressed (>2-fold expression) accompanied by a 
decrease in H3K9me2 levels (<0.5-fold expression) after G9a knockdown (Figure 4B 
and Supplementary Table 1). 
 
Pharmacological depletion of G9a in HCC cells 
BIX-01294 has been reported to be a small molecule inhibitor of G9a [15]. We have 
previously demonstrated that BIX-01294 treatment causes decreased levels of 
H3K9me2 and also inhibition of cell growth and sphere formation in Huh7 cells [16]. 
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We therefore examined whether BIX-01294 showed a similar effect in other HCC cell 
lines. Western blotting showed that BIX-01294 treatment of Huh1 cells reduced 
H3K9me2 levels, but not H3K9me3 levels, in a dose-dependent manner (Figure 5A). In 
addition, BIX-01294 inhibited cell growth and induced apoptotic cell death in a 
dose-dependent manner (Figure 5B-D). Similar to these results, non-adherent sphere 
formation was also suppressed by BIX-01294 treatment (Figure 5E and 5F). Taken 
together, these results suggest that pharmacological depletion of G9a might exert an 
anti-cancer effect in HCC cells.  
 
Effect of BIX-01294 in a xenograft transplantation model 
To further explore the anti-cancer potential of G9a inhibition, we examined the 
anti-cancer effect of the G9a inhibitor BIX-01294 in vivo using xenograft transplant 
models in non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. 
Following implantation of 2x106 Huh1 or Huh7 cells into NOD/SCID mice, 
intraperitoneal administration of BIX-01294 (10 mg/Kg) to recipient mice was started 
immediately. As a result, tumor growth was suppressed by BIX-01294 treatment in both 
Huh1- and Huh7 implanted mice (Figures 6A and 6B). Immunohistochemical analyses 
of subcutaneous tumors showed that BIX-01294 significantly reduced H3K9me2 levels 
(Figure 6C). Immunostaining for Ki-67 and CASP3 also revealed that BIX-01294 
treatment inhibited cell growth and induced apoptosis (Figure 6C). We then conducted a 
non-adherent sphere formation assay with subcutaneous tumor-derived cells. 
BIX-01294 treatment significantly impaired sphere formation (Supplementary Figure 
S5). These findings again support the possibility that BIX-01294 could be an effective 
therapeutic agent for HCC. 
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G9a expression and H3K9me2 level in primary HCC 
To begin to understand the possible relevance of G9a to primary HCC, we conducted 
immunohistochemical analyses to examine G9a expression and H3K9me2 levels in 54 
primary HCC tissues and corresponding non-tumor tissues. Tumor samples showed 
varying degrees of G9a expression and varying levels of H3K9me2 (Figure 7A). In 
contrast, G9a and H3K9me2 were weakly expressed in biliary epithelial cells, infiltrated 
lymphocytes, and periportal hepatocytes in non-tumor tissues. For G9a, 18 (33.3%) and 
36 (66.7%) of 54 HCC samples were classified as G9alow and G9ahigh, respectively. 
Similarly, for H3K9me2, 19 (35.2%) and 35 (64.8%) of 54 HCC samples were 
classified as H3K9me2low and H3K9me2high, respectively. Importantly, the number of 
G9alowH3K9me2low and G9ahighH3K9me2high tumors were found to be 10 (18.5%) and 
27 (50.0%), respectively (Figure 7B). Fisher’s exact test revealed that there was a 
statistically significant relationship between G9a expression and H3K9me2 levels 
(p<0.05).  
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DISCUSSION 
 
G9a is a member of the SET domain containing Suv39 family and catalyzes the 
dimethylation of histone H3K9 [17]. Subsequent recruitment of heterochromatin protein 
1 to H3K9me2 leads to transcriptional silencing [18]. Intriguingly, different histone 
modifications often show crosstalk in the regulation of gene expression. Ezh2 is a core 
component of polycomb repressive complex 2 and catalyzes the trimethylation of 
histone H3K27 [19]. A recent study showed that G9a and Ezh2 share genomic targets 
and interact to bring about transcriptional repression of developmental genes in mouse 
embryonic stem cells [20]. In addition, G9a co-localizes with DNA methyltransferase 1 
(DNMT1) at H3K9me2 sites and cooperates with DNMT1 in transcriptional repression 
[21]. Therefore, H3K9me2 established by G9a plays a crucial role in epigenetic 
transcriptional gene silencing. 
To gain insights into the role of G9a in HCC cells, we performed loss-of-function 
assays in cultured cells. G9a knockdown decreased H3K9me2 levels, but not H3K9me3 
levels. In line with previous reports, G9a knockdown interfered with cell proliferation 
and tumorigenicity in HCC cells. Recently, inhibition of G9a has been shown to induce 
not only apoptosis, but also autophagic cell death via the suppression of mTOR pathway 
[22, 23]. Autophagy is a cellular pathway for the clearance of damaged organelles, and 
autophagic cell death is one of the important mechanisms of cell death [24]. Further 
analyses are necessary to elucidate the role of G9a in HCC cell survival. 
EMT is a process in which epithelial cells lose their characteristics while acquiring 
the properties of mesenchymal cells. There is increasing evidence that EMT is deeply 
involved in the initiation of metastasis for cancer progression [25]. Recent studies have 
revealed that G9a is closely associated with cell migration and invasion by regulating 
                                         
12 
EMT in several cancers [12, 13]. In vitro assays showed that G9a depletion failed to 
cancel TGF-β1-induced EMT in Huh7 and PLC/PRF/5 cells, which have an epithelial 
cell morphology. However, co-IP assays on Huh7 cells showed an interaction between 
G9a and SNAIL. These findings suggest that the role of G9a in regulating EMT differs 
with the cancer types. Further analyses would be necessary to explore the subject. 
In this study, combined analyses of ChIP-seq and RNA-seq successfully identified 96 
candidate epigenetic targets of G9a. Among these, p21WAF1/CIP1, a cyclin-dependent 
kinase inhibitor, plays an important role in cell cycle arrest [26]. We previously showed 
that HCC cells treated with histone deacetylase inhibitors increases transcriptional 
activity and levels of acetylated histone H3 [27]. Taking together, the transcription of 
p21WAF1/CIP1 is silenced by histone modifications such as histone methylation and 
deacetylation in HCC cells. Tissue inhibitor of metalloproteinase 3 (TIMP3) inhibits 
tumor development via cell cycle arrest and senescence in carcinogen-induced HCC 
mouse model [28]. Restored expression of these genes followed by G9a knockdown 
might contribute to cell growth inhibition in vitro and in vivo experiments. In addition, 
differentiation marker genes such as cytokeratin 19 (CK19) and several CYP enzymes 
were de-repressed after G9a knockdown. Given that anchorage-independent growth 
ability (sphere formation capability) reflects the stemness feature of tumor cells [29], it 
is possible that the upregulation of these genes was attributable to the decreased number 
of non-adherent spheres derived from G9a knockdown cells. 
Recently, a number of HKMT inhibitors have been developed as potential therapeutic 
cancer agents [30]. Among them is BIX-01294, which is the first specific small 
molecule inhibitor of G9a. BIX-01294 has been shown to reduce H3K9me2 levels [15]. 
The mechanism of BIX-01294 inhibition is through competition with G9a substrate, 
which distinguishes it from other HKMT inhibitors which exert effects through 
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competition with the cofactor S-adenosylmethionine (SAM), the source of the 
transferred methyl group [31]. It has been reported that BIX-01294 impaired cell growth 
in other types of cancer [32, 33]. As expected, in the studies reported here, HCC cells 
treated with BIX-01294 showed reduced H3K9me2 levels. In vitro assays revealed that 
both cell proliferation and sphere formation of HCC cells were significantly impaired 
by BIX-01294 treatment in a dose-dependent manner. Subsequent xenograft 
transplantation experiments showed that BIX-01294 suppressed the onset and growth of 
subcutaneous tumors. Taken together, BIX-01294 appears to exhibit therapeutic value 
for the treatment of HCC. 
Hypoxia is a common characteristic of many solid tumors including HCC [34]. 
Intratumoral hypoxia usually induces the expression of hypoxia-inducible factor (HIF), 
which functions as a key regulator which enhances the transcription of genes involved 
in crucial biological process, including angiogenesis, cell survival, chemoresistance, and 
invasion [35]. Sorafenib is an oral multikinase inhibitor with anti-angiogenic activity 
approved for the treatment of advanced HCC [36, 37]. However, the increase in HIF-1 
expression in HCC tissues, due to hypoxia, has been shown to contribute to sorafenib 
resistance [38]. On the other hand, it has recently been reported that hypoxic stress 
inducers could increase G9a activity and global H3K9me2 levels in several cancer cell 
lines [39]. Considering these findings, it is possible that the combined use of sorafenib 
and a G9a inhibitor, such as BIX-01294, could exhibit stronger anti-HCC effects than 
sorafenib treatment alone. 
In conclusion, we have successfully demonstrated that both G9a knockdown and 
pharmacological ablation of G9a reduced H3K9me2 levels and inhibited cell 
proliferation and tumorigenicity. However, it appeared that G9a exhibited a minimal 
effect on EMT in HCC cells. Considering that a significant relationship was observed 
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between G9a expression and H3K9me2 levels in primary HCC samples, G9a might be 
an important epigenetic target in HCC treatment. Further analyses are necessary to 
elucidate the epigenetic regulatory mechanisms of G9a in HCC cells. 
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MATERIALS AND METHODS 
 
Cell culture and reagents  
Human HCC cell lines were obtained from the Health Science Research Resources 
Bank (HSRRB, Osaka, Japan). For the sphere formation assay, 1,000 cells were plated 
onto ultra-low attachment 6-well plates (Corning, Corning, NY). The number of spheres 
(>100m in diameter) was counted following 14 days of culture. For the 
pharmacological inhibition of G9a, BIX-01294 (Cayman Chemical, Ann Arbor, MI) 
was used at final concentrations of 1 M or 5M. For the induction of EMT, human 
TGF-β1 (PeproTech, Rocky Hill, NJ) was used at a final concentration of 10 g/mL. 
 
Viral production and transduction 
Lentiviral vectors (CS-H1-shRNA-EF-1-EGFP) expressing short hairpin RNA 
(shRNA) that targets the human G9a (target sequence: sh-G9a-1, 5’- 
GGATGCTTCTGAAGCTCAAGA-3’;sh-G9a-2,5’- GGTCTTCATGCTGCACCAAGA 
-3’) and luciferase (Luc) were constructed.  Recombinant lentiviruses were produced 
as described elsewhere [40]. The cells were transduced with viruses in the presence of 
protamine sulfate (10 g/mL). Huh7 cells that stably express miR200a were established 
by transduction with lentiviral vectors (pLV-miRNA) expressing miR200a (Biosettia 
Inc., San Diego, CA) and selection with puromycin. 
 
Cell growth and migration 
HCC cell proliferation was assessed using trypan blue staining after 48, 96 and 144 
hours in culture. Cell migration was assessed by the scratch-wound assay. 
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Western blotting and immunoprecipitation 
G9a-knockdown cells were selected by cell sorting for EGFP expression. These cells 
and BIX-01294-treated HCC cells were subjected to Western blot analysis using 
anti-G9a (Cell Signaling Technology, Danvers, MA), anti-tubulin (Oncogene Science, 
Cambridge, MA), anti-histone H3K9me2 and anti-histone H3 (Millipore, Billerica, MA) 
antibodies. Endogenous SNAIL was immunoprecipitated and subjected to Western 
blotting with rabbit anti-SNAIL (Cell Signaling Technology) and mouse anti-G9a 
(Abcam, Cambridge, MA) antibodies. 
 
Immunocytochemistry 
Cells were fixed with 2% paraformaldehyde and blocked with normal goat serum. 
Cells were then stained with anti-G9a (Cell Signaling Technology), anti-E-cadherin 
(Cell Signaling Technology), anti-caspase 3 (CASP3; Chemicon, Temecula, CA), and 
anti-H3K9me3 (Millipore) antibodies, followed by incubation with Alexa 555- or Alexa 
488-conjugated immunoglobulin G (IgG) (Molecular Probes, Eugene, OR) antibodies. 
Cells were coverslipped using a mounting medium that contained 
4’,6-diamidino-2-phenylindole dihydrochloride (DAPI; Vector Laboratories, 
Burlingame, CA).  
 
Quantitative real-time PCR 
Quantitative real-time PCR was performed with an ABI PRISM 7300 Sequence 
Detection System (Applied Biosystems, Foster City, CA) using the Universal Probe 
Library System (Roche Diagnostics, Mannheim, Germany) according to the 
manufacturer’s directions. The sequences of primers are listed in Supplementary Table 
2. For the evaluation of miRNA expression, miRNA-specific TaqMan miRNA assays 
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(Applied Biosystems) for miR-200a, miR-200b, and U6 (internal control) were 
performed according to the manufacturer’s directions. 
 
RNA-sequencing 
RNA-Seq was performed as previously described [41]. In brief, total RNA was 
subjected to reverse transcription and amplified through 16 cycles with SMARTer Ultra 
Low Input RNA Kit for Sequencing v3 (Clontech). After sonication, libraries were 
generated using 50 ng fragmented DNA with a NEBNext Ultra DNA Library Prep Kit 
(New England BioLabs). After quantification of the libraries with a high-sensitivity 
Chip using Bioanalyzer (Agilent), sequencing of the samples was performed using a 
Hiseq1500 (Illumina). Gene expression values were calculated as reads per kilobase of 
exon unit per million mapped reads using Cufflinks (version 2.2.1). 
 
ChIP-sequencing 
ChIP sequencing (ChIP-Seq) was also cperformed as previously described [42]. In 
brief, 1×107 Huh7 cells were subjected to immunoprecipited using anti-H3K9me2 
(Millipore, Billerica, MA) antibodies. To evaluate the histone modification H3K9me2 in 
each gene, normalized tag numbers in the region from 2 kb upstream to 2 kb 
downstream of the transcription start site (TSS) were separated by reads per million 
(RPM) mapped reads of the corresponding input.  
 
Xenograft transplantation 
NOD/SCID mice (Sankyo Laboratory Co. Ltd., Tsukuba, Japan) were bred and 
maintained in accordance with our institutional guidelines for the use of laboratory 
animals. A total of 2 x 106 HCC cells stably expressing shRNA against G9a or 
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luciferase were implanted into the subcutaneous space on the right and left sides of the 
backs of recipient NOD/SCID mice, respectively. In the BIX-01294 treatment model, a 
total of 2 x 106 Huh1 or Huh7 cells were implanted into the subcutaneous space on the 
backs of NOD/SCID mice. BIX-01294 (10 mg/Kg) was administered intraperitoneally 3 
times a week. Tumor formation and growth were observed weekly. Subcutaneous 
tumors were also subjected to hematoxylin and eosin (H&E) staining and 
immunohistochemistry with anti-H3K9me2, anti-CASP3, and anti-Ki67 (DAKO, 
Carpinteria, CA) antibodies. For the analyses of xenograft tumors, small pieces of tumor 
were digested in DMEM containing 5 mg/mL collagenase type II (Roche). The cell 
suspension was centrifuged on Ficoll (IBL, Gunma, Japan) to remove dead cells and 
debris. The harvested cells were subjected to sphere formation assays. All experiments 
were performed in accordance with the institutional guidelines for the use of laboratory 
animals. 
 
Patients and surgical specimens 
A total of 54 tumor and non-tumor liver tissue pairs were subjected to histological 
examination. All patients provided informed consent. They included 41 men and 13 
women whose average age was 67.6 years (range: 27–84 years). Paraffin embedded 
sections of tumors and surrounding non-tumor tissues were examined by H&E staining 
and immunohistochemistry with anti-G9a and anti-H3K9me2 antibodies. Based on the 
percentage of cells that strongly expressed these markers, HCC tissues were divided 
into two groups: G9alow or H3K9me2low (<50% of tumor cells) and G9ahigh or 
H3K9me2high (≥50% of tumor cells).  
 
Statistical analysis 
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Data are presented as the mean  standard error of the mean (SEM). Statistical 
differences between 2 groups were analyzed by either Mann-Whitney U test or 
Chi-square test. Fisher’s exact test was used to assess the relationship between 
H3K9me2 levels and G9a expression. P values less than .05 were considered 
significant. 
 
Accession numbers 
Data of RNA-seq and ChIP-seq were deposited in DNA Data Bank of Japan 
(DRA005376). 
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Figure Legends 
 
Fig. 1 Basal expression levels of G9a and H3K9me2 in Huh1, Huh7, PLC/PRF/5, and 
Huh6 cells. Immunocytochemical analyses for G9a expression (red) and H3K9me2 
levels (green) in HCC cells. Nuclear DAPI staining (blue) is also shown. Scale bar = 
200 m. 
 
Fig. 2 G9a knockdown in HCC cells. (A) Stable knockdown cells were selected by cell 
sorting for EGFP expression, and subjected to Western blot analysis using anti-G9a, 
anti-tubulin, anti-H3K9me2, and anti-H3 antibodies. Tubulin and histone H3 were used 
as loading controls. (B) Inhibition of cell proliferation in G9a knockdown HCC cells 
cultured for 48, 96, and 144 hours after seeding. Data sets were obtained from three 
independent experiments. *Statistically significant (p < 0.05). (C) Bright-field images of 
G9a knockdown HCC cells showing non-adherent spheres formed after 14 days of 
culture. Fluorescence images are shown in the insets. Scale bar = 100 m. (D) Number 
of large spheres generated from 1,000 cells transduced with indicated viruses. Data sets 
were obtained from three independent experiments. *Statistically significant (p < 0.05). 
 
Fig. 3 TGF-β1 treatment in G9a knockdown HCC cells. (A) Co-immunoprecipitation of 
endogenous SNAIL and G9a in Huh7 cells. 293T cells were used as positive control. 
(B) Bright-field images of Huh7 cells treated with TGF-β1 for 48 hours. Fluorescence 
images are shown in insets. Scale bar = 100 m. (C) Immunocytochemical analyses for 
G9a (green) and E-cadherin (red) in Huh7 cells. Nuclei stained with DAPI (blue) are 
                                         
27 
also shown. Scale bar = 100 m. (D) Real-time RT-PCR analysis of the expression of 
EMT markers in Huh7 cells after TGF-β1 treatment for 48 hours. Data sets were 
obtained from three independent experiments. were obtained from three independent 
experiments. *Statistically significant (p < 0.05). 
 
Fig. 4 Combined analyses of ChIP-seq and RNA-seq in Huh7 cells. (A) Number of 
genes with H3K9me2 enrichment detected by ChIP-seq analysis in G9a knockdown 
cells and control cells. (B) Scatter plot depicting the association between H3K9me2 
levels and the expression levels of RefSeq genes in G9a knockdown cells relative to 
control cells. The 96 genes showing both decrease in H3K9me2 levels >2-fold and 
increase in expression levels >2-fold are indicated by red dots. 
 
Fig. 5 In vitro assays of HCC cells treated with BIX-01294. (A) Huh1 cells treated or 
not with BIX-01294 (1 or 5M) for 48 hour were subjected to Western blot analysis 
using anti- H3K9me2 and anti-H3 antibodies. (B) Dose-dependent inhibition of 
proliferation in BIX-01294-treated Huh1 cells. Data sets were obtained from three 
independent experiments. *Statistically significant (p < 0.05). (C) Apoptotic cells were 
identified by immunocytochemical staining for active CASP3 (Red). Nuclear DAPI 
staining (blue) is also shown. Scale bar = 100 m. (D) Percentage of apoptotic cells. 
Data sets were obtained from three independent experiments. *Statistically significant 
(p < 0.05). (E) Bright-field images showing non-adherent spheres formed by Huh1 cells 
following 14 days of culture in the presence or absence of BIX-01294. Scale bar = 100 
m. (F) Number of large spheres (>100 m in diameter) generated from 1,000 cells. 
Data sets were obtained from three independent experiments. *Statistically significant 
(p < 0.05). 
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Fig. 6 Xenograft transplantation assays in NOD/SCID mice. (A) A total of 2×106 Huh1 
or Huh7 cells were transplanted into the subcutaneous space of NOD/SCID mice. 
Growth of subcutaneous tumors was suppressed by BIX-01294 treatment 8 weeks after 
transplantation (N=5 per group). (B) Volume of subcutaneous tumors was determined at 
8 weeks after transplantation (right panel). *Statistically significant (p < 0.05). (C) 
Hematoxylin and eosin (H&E) staining and immunohistochemical analyses of 
representative samples of subcutaneous tumor. 
 
Fig. 7 G9a expression and H3K9me2 levels in HCC surgical samples. (A) 
Representative immunohistochemical staining for G9a and H3K9me2 in tumor and 
non-tumor tissues. Scale bar = 100 m. (B) Positive correlation between G9a expression 
and H3K9me2 levels. 
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Supplementary Figure Legends 
 
Supplementary Fig. 1 Xenograft transplantation in NOD/SCID mice. (A) In total, 
2×106 G9a knockdown Huh1 and Huh7 cells were separately implanted into the 
subcutaneous space of NOD/SCID mice. G9a knockdown cells developed apparently 
smaller tumors in the right subcutaneous space (arrows) than sh-Luc-expressing control 
cells in the left space (arrowheads) 6 weeks after the transplantation (N=5 per group). 
(B) Tumor volume was estimated 6 weeks after transplantation. *Statistically significant 
(p < 0.05). 
 
Supplementary Fig. 2 TGF-β1-induced EMT in G9a knockdown PLC/PRF/5 cells. (A) 
Real-time RT-PCR analysis of G9a expression in stable G9a knockdown cells. Data sets 
were obtained from three independent experiments. *Statistically significant (p <0.05). 
(B) Bright-field images of PLC/PRF/5 cells treated with TGF-β1 for 48 hours. 
Fluorescence images are shown in insets. Scale bar = 100 m. (C) Immunocytochemical 
analyses for G9a (green) and E-cadherin (red) expression in PLC/PRF/5 cells. Scale bar 
= 100 m. (D) Real-time RT-PCR analysis of the expression of EMT markers in 
PLC/PRF/5 cells after TGF-β1 treatment for 48 hours. Data sets were obtained from 
three independent experiments. *Statistically significant (p < 0.05). 
 
Supplementary Fig. 3 Wound healing assay of Huh7 cells. No remarkable differences 
in migration ability were observed between control and G9a knockdown cells after 
TGF-β1 treatment. 
 
Supplementary Fig. 4 Role of miR-200 in TGF-β1-induced EMT in Huh7 cells. (A) 
                                         
30 
Expression of miR-200a and 200b in stable G9a knockdown cells was analyzed using 
real-time RT-PCR and normalized to U6. Data sets were obtained from three 
independent experiments. (B) Real-time RT-PCR analysis of miR-200a expression in 
G9a knockdown cells stably expressing miR-200a. Data sets were obtained from three 
independent experiments. (C) Immunocytochemical analyses of G9a (green) and 
E-cadherin (red) expression in G9a knockdown cells with miR-200a overexpression. 
Nuclei stained with DAPI (blue) are also shown. Scale bar = 100 m. 
 
Supplementary Fig. 5 Non-adherent sphere formation assay of xenograft 
tumor-derived cells. (A) Bright-field images of tumor cells in non-adherent spheres 
formed after 14 days of culture. (B) Number of large spheres (>100m in diameter) 
generated from 1,000 tumor-derived cells. Data sets were obtained from three 
independent experiments. *Statistically significant (p < 0.05). 
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